Skip to main content
SpringerLink
Log in
Book cover

Peptides and Non Peptides of Oncologic and Neuroendocrine Relevance pp 161–168Cite as

Hormonal Treatments of Endocrine-Dependent Tumors: Preclinical Aspects

  • Conference paper

  • 60 Accesses

Abstract

Breast and prostate carcinomas are the most frequently diagnosed diseases in the group of the so-called endocrine-dependent tumors. These diseases are given this name because their development and maintenance, and in several instances their progression, are sustained by the presence of gonadal hormones in the bloodstream, namely estrogens in females and androgens, particularly testosterone, the main testicular androgen, in males.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Auclerc G., Antoine E.C., Cajfinger F., Brunet-Pommeyrol A., Agazia C, Khayat D. (2000). Management of advanced prostate cancer. Oncologist, 5, 36–44.

    Article  PubMed  CAS  Google Scholar 

  • Bologna M., et al. (1992). Anti-androgens and 5alpha-reductase inhibition of the proliferation rate in PC3 and DU145 human prostatic cancer cell line. Curr Ther Res, 51,799–813.

    CAS  Google Scholar 

  • Bologna M., et al. (1995). Finasteride dose-dependently reduces the proliferation rate of the LnCAP human prostatic cancer cell line in vitro. Urology, 45, 282–290.

    Article  PubMed  CAS  Google Scholar 

  • Bonneterre J., et al. (2000). Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol, 18, 3748–3757.

    PubMed  CAS  Google Scholar 

  • Buzdar A. and Hortobagyi G. (1998). Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol, 16, 348–353.

    PubMed  CAS  Google Scholar 

  • Coltman C.A., et al. (1999). Prostate cancer prevention trial (PCPT) update. Eur Urol, 35, 544–547.

    Article  PubMed  Google Scholar 

  • Cook T., Sheridan W.P. (2000). Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist, 5, 162–168.

    Article  PubMed  CAS  Google Scholar 

  • Cummings S., et al. (1999). The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomised trial. Multiple Outcomes of Raloxifene Evaluation. JAMA, 281, 2189–2197.

    Article  PubMed  CAS  Google Scholar 

  • Denis L. and Griffiths K. (2000). Endocrine treatment in prostate cancer. Semin Surg Oncol, 18, 52–74.

    Article  PubMed  CAS  Google Scholar 

  • Dowsett M., et al. (1995). In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in post-menopausal patients with breast cancer. Clin Cancer Res, 1, 1511–1515.

    PubMed  CAS  Google Scholar 

  • Filardo E., et al. (2000). Estrogen-induced activation of Erk-i and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via fraws-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol, 14, 1649–1660.

    Article  PubMed  CAS  Google Scholar 

  • Fisher B., et al. (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-i Study. J Natl Cancer Inst, 90, 1371–1388.

    Article  PubMed  CAS  Google Scholar 

  • Fisher B., et al. (1999). Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet, 353, 1993–2000.

    Article  PubMed  CAS  Google Scholar 

  • Fradet Y., et al. (1999). Dietary fat and prostate cancer progression and survival. Eur Urol, 35, 388–391.

    Article  PubMed  CAS  Google Scholar 

  • Gale K., et al. (1994). Hormonal treatment for metastatic breast cancer: an Eastern Cooperative Oncology Group Phase III trial comparing aminogluthetimide to tamoxifen. Cancer, 73,354–361.

    Article  PubMed  CAS  Google Scholar 

  • Gormley G. (1996). 5alpha-reductase inhibitors in prostate cancer. Endocrine-Related Cancer, 3, 57–63.

    Article  CAS  Google Scholar 

  • Ingle J., et al. (1999). Evaluation of tamoxifen plus letrozole with assessment of pharma-cokinetic interaction in postmenopausal women with metastatic breast cancer. Clin Cancer Res, 5, 1642–1649.

    PubMed  CAS  Google Scholar 

  • MacNeill R, et al. (1992). The influence of aminoglutethimide and its analogue rogle- timide on peripheral aromatisation in breast cancer. Br I Cancer, 66, 692–697.

    Article  CAS  Google Scholar 

  • Mor G., et al. (1998). Macrophages, estrogen and the microenvironment of breast cancer. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity. J Steroid Biochem Mole Biol, 67, 403–411.

    Article  CAS  Google Scholar 

  • Mouridsen H., et al. (2001). Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol, 19, 2596–2606.

    PubMed  CAS  Google Scholar 

  • Nabholtz J., et al. (2000). Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol, 18, 3758–3767.

    PubMed  CAS  Google Scholar 

  • Paech K. et al. (1997). Differential ligand activation of estrogen receptors ERalpha and ERbeta at APi sites. Science, 277, 1508–1510.

    Article  PubMed  CAS  Google Scholar 

  • Petterson K. and Gustafsson J. (2001). Role of estrogen receptor beta in estrogen action. Annu Rev Physiol, 63, 165–192.

    Article  Google Scholar 

  • Porter W., et al. (1997). Functional synergy between the transcription factor Spi and the estrogen receptor. Mol Endocrinol, 11, 1569–1580.

    Article  PubMed  CAS  Google Scholar 

  • Powles T., et al. (1998). Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet, 352, 98–101.

    PubMed  CAS  Google Scholar 

  • Sanford E.J., et al. (1977). The effects of castration on adrenal testosterone secretion in men with prostatic carcinoma. J Urol, 118, 1019–1021.

    PubMed  CAS  Google Scholar 

  • Santen R. and Harvey H. (1999). Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer, 6, 75–92.

    Article  PubMed  CAS  Google Scholar 

  • Santen R., et al. (1990). Endocrine treatment of breast cancer in women. Endocr Rev, 11, 221–265.

    Article  PubMed  CAS  Google Scholar 

  • Siiteri P.K. (1987). Adipose tissue as a source of hormones. Am J Clin Nutr, 45, 277–82.

    PubMed  CAS  Google Scholar 

  • Small E. and Srinivas S. (1995). The anti-androgen withdrawal syndrome: experience in a large cohort of unselected patients with advanced prostate cancer. Cancer, 76, 1428–1434.

    Article  PubMed  CAS  Google Scholar 

  • Smith I., et al. (1982). Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res, 42 (8 Suppl), 3430S–3433S.

    PubMed  CAS  Google Scholar 

  • Takayama K., et al. (1997). Transcriptional regulation of CYP19 gene (aromatase) expression in adipose stromal cells in primary culture. J Clin Endocrinol Metab, 82, 600–606.

    Article  PubMed  Google Scholar 

  • Taplin M., et al. (1995). Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med, 332, 1393–1398.

    Article  PubMed  CAS  Google Scholar 

  • Veronesi U., et al. (1998). Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet, 352, 93–97.

    PubMed  CAS  Google Scholar 

  • Zhang Y., et al. (1997). Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med, 336, 661–617.

    Article  Google Scholar 

  • Zumoff B. (1998). Does postmenopausal estrogen administration increase the risk of breast cancer? Contributions of animal, biochemical, and clinical investigative studies to a resolution of the controversy. Proc Soc Exp Biol Med, 217, 30–37.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. P. Magni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Motta
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology, University of Milan, Milan, Italy

    Eugenio E. Müller

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Italia

About this paper

Cite this paper

Magni, P., Motta, M. (2003). Hormonal Treatments of Endocrine-Dependent Tumors: Preclinical Aspects. In: Müller, E.E. (eds) Peptides and Non Peptides of Oncologic and Neuroendocrine Relevance. Springer, Milano. https://doi.org/10.1007/978-88-470-2085-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-2085-6_15

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-2170-9

  • Online ISBN: 978-88-470-2085-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation